This study is looking at how Dupilumab, a medication given by injection, affects people with moderate to severe asthma. We want to see if Dupilumab can improve how well your lungs clear mucus (mucociliary clearance, or MCC). You might be able to join if you are over 18, have moderate to severe asthma, and are already taking medium to high doses of inhaled steroids. Some participants will receive Dupilumab, while others will receive a placebo (an inactive substance that looks like the study drug). We will measure changes in MCC after 12 weeks of treatment to see if Dupilumab is effective. The current recruitment status is unclear.

Study design

This is a single-center, randomized, placebo-controlled study involving 30 participants. It compares Dupilumab to a placebo.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

The primary measurement for this study is taken 12 weeks after the start of treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.